Avacta Group PLC Avacta's CSO to Present at Major US Conference

TIDMAVCT

Avacta Group PLC

12 June 2019

12 June 2019

Avacta Group plc

("Avacta", the "Company" or the "Group")

Avacta's Chief Scientific Officer to Present at Major US Conference

Avacta Group plc (AIM: AVCT), the developer of Affimer(R) biotherapeutics and reagents, is pleased to announce that its Chief Scientific Officer, Dr Amrik Basran, will be presenting at the Next Generation Protein Therapeutics & Bioconjugates conference in San Francisco, California on 19 June 2019.

Dr Basran's presentation, 'Affimer Therapeutics: A Novel Human Scaffold for the Generation of Bi-specific Molecules', will give an overview of the benefits of using Affimer technology to generate bispecific drug molecules.

Bispecific therapy - single molecules that engage with two drug targets simultaneously - is a major area of focus in large pharma immuno-oncology programmes. Avacta has highlighted bispecifics as a key element of its therapeutic pipeline strategy, alongside the development of its novel tumour microenvironment activated drug conjugates.

Dr Basran's presentation will highlight the stability, solubility and ease of manufacturing functional Affimer bispecifics incorporating Avacta's proprietary serum half-life extension technology (Affimer XT(TM) ), as well as PD-L1 and LAG-3 Affimer inhibitors.

- Ends -

For further information from Avacta Group plc, please contact:

 
    Avacta Group plc                           Tel: [phone] 
     Alastair Smith, Chief Executive            www.avacta.com 
     Officer 
     Tony Gardiner, Chief Financial 
     Officer 
    finnCap Ltd (Nominated Adviser             Tel: [phone] 
     and Joint Broker)                          www.finncap.com 
     Geoff Nash / Giles Rolls - Corporate 
     Finance 
     Tim Redfern - ECM                          Tel: [phone] 
                                                Tel: [phone] 
     WG Partners (Joint Broker)                 www.wgpartners.co.uk 
     Nigel Birks / Nigel Barnes 
     David Wilson / Claes Spang 
    Turner Pope Investments                    Tel: [phone] 
     James Pope / Ben Turner                    www.turnerpope.com 
 
     Yellow Jersey PR (Financial Media 
     and IR)                                    Tel: [phone] 
     Sarah Hollins                              Tel: [phone] 
     Harriet Jackson                            [e-mail] 
 
     Zyme Communications (Trade and             Tel: [phone] 
     Regional Media)                            [e-mail] 
     Katie Odgaard 
 

About Avacta Group plc - www.avacta.com

Avacta's principal focus is on its proprietary Affimer(R) technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.

Antibodies dominate markets worth in excess of $100bn despite their shortcomings. Affimer technology has been designed to address many of these negative performance issues, principally; the time taken to generate new antibodies, the reliance on an animal's immune response, poor specificity in many cases, and batch to batch variability. Affimer technology is based on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of protein targets.

Avacta has a pre-clinical biotech development programme with an in-house focus on immuno-oncology as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics.

To register for news alerts by email go to www.avacta.com/investor-news-email-alerts

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

NRACKDDKPBKDOAD

(END) Dow Jones Newswires

June 12, 2019 02:00 ET (06:00 GMT)